Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06025877 · ClinicalTrials.gov registry record
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
A clinical trial of Alzheimer Disease and Mild Cognitive Impairment, sponsored by C2N Diagnostics.
- Active
- Registry status
- 400
- Enrollment target
- 9
- Study locations
NCT06025877: Active study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by C2N Diagnostics.
NCT06025877 is a study of Alzheimer Disease and Mild Cognitive Impairment that is active but no longer recruiting, run by C2N Diagnostics. The registered enrollment target is 400 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (85% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06025877, a study of Alzheimer Disease and Mild Cognitive Impairment, is active but no longer recruiting, sponsored by C2N Diagnostics.
- ACTIVE NOT RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 9
- Study locations
Study Summary
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia. MCI impacts 12-18% of people in the United States over age 60 years (Alzheimer's Association. Mild Cognitive Impairment (MCI) available at https://www.alz.org/alzheimers-dementia/what-is-dementia/related\_conditions/mild-cognitive-impairment. Accessed August 16, 2022). MCI does not substantially interfere with daily activities, although complex functional tasks may be performed less efficiently (Knopman DS, Petersen RC. Mild cognitive impairment and mild dementia: a clinical perspective. Mayo Clin Proc. 2014;89(10):1452-1459. doi:10.1016/j.mayocp.2014.06.019). Approximately 30% of MCI patients have Alzheimer's disease (AD) as a cause of their symptoms (Lopez,OL, Kuller LH, Becker JT, et al. Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol. 2007;64(3):416-420.doi:10.1001/archneur.64.3.416)). In contrast, dementia is defined by chronic, acquired loss of two or more cognitive abilities caused by brain disease or injury, often associated with significant interference with the ability to function at work or at usual activities. (Knopman DS, Petersen RC. Mild cognitive impairment and mild dementia: a clinical perspective. Mayo Clin Proc. 2014;89(10):1452-1459. doi:10.1016/j.mayocp.2014.06.019). Approximately 60-80% of dementia patients have AD as a cause of their symptoms (Alzheimer's Association. Mild Cognitive Impairment (MCI) available at https://www.alz.org/alzheimers-dementia/what-is-dementia/related\_conditions/mild-cognitive-impairment. Accessed August 16, 2022).
Conditions Studied
Interventions
- OTHER PrecivityAD2(TM) blood test
Study Locations (9)
California
- UCSF Memory and Aging Center - San Francisco
- Pacific Brain Health Center - Santa Monica
Missouri
- Sharlin Health and Neurology - Ozark
- C2N Diagnostics - St Louis
Illinois
- Advocate Memory Center - Park Ridge
Indiana
- Josephson Wallack Munshower Neurology, P.C. - Indianapolis
Louisiana
- Tulane Doctors Neurosurgery Clinic - New Orleans
Michigan
- Memorial Healthcare Institute for Neuroscience - Owosso
South Carolina
- Palmetto Primary Care Physicians - Summerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-11-15 |
| Est. Completion | 2025-04-30 |
What the registry record for NCT06025877 still lists
NCT06025877 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (85% lower).
The record links to 6 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which PrecivityAD2(TM) blood test is the first listed.
NCT06025877 lists 9 locations in 7 states (California, Missouri, Illinois).
Frequently Asked Questions
What is clinical trial NCT06025877 about?
NCT06025877 is a clinical study titled "Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey". There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia. MCI impacts 12-18% of people in the United States over age 60 years (Alzheimer's Association. Mild Cognitive Impairment (MCI) available at https:/...
What is the current status of trial NCT06025877?
This trial is currently active not recruiting. The enrollment target is 400 participants. The study started on 2023-11-15. Estimated completion is 2025-04-30.
What conditions does trial NCT06025877 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Impairment, Cognitive Decline.
What interventions are being tested in trial NCT06025877?
The interventions under investigation include: PrecivityAD2(TM) blood test (OTHER).
Who is sponsoring clinical trial NCT06025877?
This trial is sponsored by C2N Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06025877 being conducted?
This trial has 9 study locations across California, Illinois, Indiana, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06025877's enrollment target sits among peer trials
400 64th of 306 higher than 243 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI